ARHGAP23 Activators
ARHGAP23 Activators can act on a variety of cellular processes, typically requiring heightened ARHGAP23 activity to maintain cellular homeostasis. Compounds like Phorbol 12-myristate 13-acetate (PMA) and Forskolin exert their effects on ARHGAP23 indirectly through other pathways. For instance, PMA activates PKC, which can then promote Rho GTPase cycling. This increase in cycling necessitates more ARHGAP23 to hydrolyze active GTP-bound Rho proteins to their inactive GDP-bound state. Similarly, Forskolin increases cAMP levels, impacting a signaling cascade that would involve ARHGAP23's regulation of Rho GTPases.
Chemicals like U0126, which selectively inhibits MEK1/2, also affect ARHGAP23 activity indirectly. When MEK1/2 activity is inhibited, this disruption in the ERK signaling pathway may lead to an increase in Rho GTPase activity. Subsequently, higher levels of ARHGAP23 are required to maintain the balance between the active and inactive states of Rho GTPases. This class of chemicals effectively contributes to elevating the ARHGAP23 protein's regulatory role in these complex pathways, each influencing the protein's activity by affecting interconnected signaling networks.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PKC activator that can promote Rho GTPase cycling, requiring elevated ARHGAP23 activity to maintain cellular homeostasis. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Adenylyl cyclase activator that increases cAMP levels, potentially triggering a signaling cascade that could involve ARHGAP23 for Rho GTPase modulation. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
JNK pathway activator, potentially causing a surge in Rho GTPase activity which would necessitate higher ARHGAP23 activity for regulation. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
Analog of cAMP that activates PKA and subsequently can engage pathways that require ARHGAP23-mediated Rho GTPase regulation. | ||||||
8-pCPT-2′-O-Me-cAMP | 634207-53-7 | sc-257020 | 1 mg | $306.00 | 5 | |
Selective activator of Epac, which modulates Rap1 GTPase, possibly shifting the balance of Rho GTPases and requiring elevated ARHGAP23 activity. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Broad-spectrum PKC inhibitor that may disrupt signaling pathways involving Rho GTPases, requiring increased ARHGAP23 activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-selective PDE inhibitor that elevates intracellular cAMP and cGMP, potentially leading to increased ARHGAP23 activity for Rho GTPase regulation. | ||||||
EHT 1864 | 754240-09-0 | sc-361175 sc-361175A | 10 mg 50 mg | $213.00 $889.00 | 12 | |
Rac family small GTPase inhibitor that may disrupt the balance among Rho GTPases, necessitating increased ARHGAP23 activity. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Calcium ionophore that may trigger calcium-sensitive signaling cascades involving Rho GTPases, requiring elevated ARHGAP23 activity. | ||||||